Insights

(CHICAGO) Katten announced that the firm was recognized as a leader in 42 practice areas and 108 attorneys were individually ranked in the 2026 edition of the Chambers USA guide.

Katten's highest rankings were in the categories of Bankruptcy/Restructuring, Corporate/M&A, Healthcare, Intellectual Property: Trademark, Copyright & Trade Secrets, Litigation: White-Collar Crime & Government Investigations, Public Finance, Real Estate and Real Estate: Finance.

(LONDON) Katten Muchin Rosenman UK LLP announced that two partners have joined in London, launching the Structured Products and Derivatives practice and advancing the firm's strategic growth.

Joining the firm to lead the new practice is Jennifer Kafcas, working alongside Alvino van Schalkwyk, to enhance the firm's capabilities in the structured finance and financial markets space. Together, they bring comprehensive strengths across high-value, complex derivatives and structured products transactions, covering the full range of structuring, legal and documentation considerations across all major asset classes.

Katten announced that Kimberly Smith, partner and global chair of the firm's Corporate department, has been selected to the inaugural Forbes America's Top Women Lawyers list for 2026. The list and accompanying feature story spotlight a rarefied group of elite attorneys in private practice and is based on a rigorous, multi-stage process of editorial research and analysis designed to identify the finest in the profession.

CHICAGO) Katten announced that 23 practice areas were recognized in the Legal 500 United States 2026 guide. In addition, seven attorneys earned individual distinctions — three in the Hall of Fame and four as Leading Partners — while 79 attorneys were highlighted as recommended individuals in the guide's editorial commentary.

On May 18, a federal jury in Massachusetts returned a $885 million verdict against Takeda Pharmaceuticals, finding that Takeda entered into an anticompetitive patent settlement that compensated a generic manufacturer to delay launching a generic version of its IBS drug, Amitiza® (lubiprostone). In re Amitiza Antitrust Litigation, No. 1:21-cv-11057 (D. Mass.). The suit consolidated complaints filed by a class of direct purchasers (wholesalers), five individual retailers (pharmacy chains), and a class of indirect purchasers (end payors). The outcome is significant because it is the first jury trial win for private antitrust plaintiffs in a suit challenging a patent settlement reverse payment. Previous suits have either settled or gone to trial and lost. For Brand and Generic pharmaceutical manufacturers, this may lead to further scrutiny of past settlements.